common
techniqu
use
sensit
specif
diagnost
viru
detect
clinic
sampl
pcr
identifi
one
sever
virus
one
assay
howev
diagnost
microarray
contain
probe
human
pathogen
could
replac
hundr
individu
pcrreaction
remov
need
clear
clinic
hypothesi
regard
suspect
pathogen
establish
diagnost
platform
random
amplif
subsequ
microarray
identif
viral
pathogen
clinic
sampl
show
polymeraseamplif
divers
set
clinic
sampl
gener
enough
viral
materi
success
identif
microbi
detect
array
demonstr
potenti
microarray
techniqu
broadspectrum
pathogen
detect
conclud
method
detect
dna
rna
viru
present
sampl
well
differenti
differ
viru
subtyp
propos
assay
diagnost
analysi
virus
clinic
sampl
common
method
choic
clinic
pathogen
identif
polymeras
chain
reaction
pcr
sensit
specif
method
howev
pcr
reaction
provid
identif
one
specif
viru
group
relat
virus
thu
clinic
hypothesi
regard
suspect
pathogen
need
guid
decis
pcr
analys
perform
result
larg
number
pcr
protocol
need
facilit
identif
human
pathogen
dna
microarray
test
emerg
promis
new
technolog
broadspectrum
viru
detect
make
possibl
test
presenc
thousand
virus
simultan
sever
microarray
platform
develop
detect
known
virus
well
novel
virus
relat
known
viru
famili
test
clinic
sampl
mostli
respiratori
sampl
microarray
contain
probe
human
pathogen
could
use
diagnost
analysi
well
research
purpos
environment
sampl
epidemiolog
surveil
moreov
clinic
syndrom
symptom
might
difficult
determin
virus
test
order
establish
correct
diagnosi
sinc
mani
virus
present
similar
symptom
reason
variou
multiplex
assay
viru
panel
util
pcr
method
establish
howev
microarray
could
view
extend
pathogen
panel
cover
virus
bacteria
increas
chanc
correct
identif
one
sever
pathogen
even
situat
without
prior
knowledg
suspicion
etiolog
without
preamplif
clinic
sampl
pcr
viru
cultur
microarray
sensit
enough
pathogen
identif
clinic
sampl
sinc
viru
titr
normal
detect
limit
exampl
diagnost
human
papilloma
viru
hpv
specif
microarray
util
hpvspecif
pcramplif
prior
microarray
hybrid
differ
pcrbase
random
amplif
develop
achiev
enough
materi
success
identif
howev
studi
shown
pcrbase
whole
genom
amplif
wga
may
gener
incomplet
coverag
genom
instead
use
multipl
displac
amplif
mda
base
wga
isotherm
amplif
polymeras
polymeras
highest
process
rate
report
base
everi
time
bind
error
rate
base
allow
good
coverag
across
genom
averag
length
produc
kb
compar
kb
taq
polymeras
prior
microarray
analysi
use
human
genom
dna
analysi
bacteri
dna
analysi
howev
polymeras
amplifi
rna
short
dna
fragment
bp
cdna
gener
random
hexam
overcom
method
whole
transcriptom
amplif
wta
includ
ligat
step
prior
amplif
result
cdna
fragment
ligat
larger
transcriptom
effici
amplifi
polymeras
investig
real
life
util
sensit
microarray
techniqu
diagnost
setup
establish
protocol
includ
pretreat
nucleic
acid
na
purif
follow
microarray
analysi
dna
rna
virus
divers
set
clinic
sampl
show
gener
enough
materi
success
identif
lawrenc
livermor
microbi
detect
array
llmda
demonstr
potenti
microarray
techniqu
broadspectrum
pathogen
detect
clinic
sampl
exempt
review
ethic
committe
system
obtain
inform
consent
obtain
committe
biomed
research
ethic
capit
region
accord
danish
law
qualiti
control
assay
develop
project
sapoviru
clarth
microarray
genomica
hpv
pcr
perform
stratagen
appli
biosystem
thermal
cycler
fiveto
twohundr
microlit
clinic
sampl
centrifug
g
minut
supernat
filter
mm
ultrafre
mc
spin
filter
millipor
g
minut
dnase
treat
u
dnasei
amplif
grade
invitrogen
hour
room
temperatur
shaken
thermomix
ah
diagnost
viral
na
extract
use
purelink
viral
rnadna
kit
invitrogen
without
addit
carrier
rna
extract
viral
na
elut
ml
dnasernasefre
steril
water
store
immedi
use
revers
transcript
purifi
viral
rna
perform
use
superscript
vilo
cdna
synthesi
kit
invitrogen
accord
protocol
briefli
ml
extract
viral
rna
put
mlreaction
contain
superscript
enzym
random
primer
incub
hour
enzym
inactiv
minut
sampl
store
immedi
use
viral
dna
amplifi
polymeras
amplif
use
genomiphi
amplif
kit
ge
healthcar
replig
midi
kit
typic
yield
mg
ml
reaction
qiagen
follow
manufactur
protocol
briefli
use
genomiphi
amplif
kit
ml
purifi
dna
ad
ml
sampl
buffer
incub
minut
cool
ice
ten
microlit
genomiphi
reaction
ad
contain
polymeras
random
primer
reaction
incub
k
hour
reaction
termin
incub
minut
amplifi
viral
dna
store
immedi
use
briefli
use
replig
midi
kit
ml
purifi
dna
mix
ml
denatur
buffer
incub
room
temperatur
minut
reaction
termin
addit
ml
stop
solut
thirti
microlit
replig
reaction
mix
contain
random
primer
ad
reaction
incub
hour
reaction
termin
incub
minut
amplifi
materi
purifi
use
qiaamp
dna
mini
kit
qiagen
use
modifi
protocol
wwwqiagencom
check
puriti
concentr
use
nanodrop
spectrophotomet
thermo
scientif
agaros
gel
electrophoresi
dna
store
immedi
use
microarray
analysi
viral
na
amplif
dna
rna
viru
use
describ
wta
method
use
quantitect
whole
transcriptom
amplif
kit
typic
yield
mg
ml
reaction
qiagen
accord
manufactur
protocol
except
revers
transcript
step
replac
superscript
vilo
kit
invitrogen
describ
wta
protocol
includ
sequenti
reaction
first
revers
transcript
reaction
gener
cdna
secondli
ligat
gener
cdna
larger
transcriptom
thirdli
gener
transcriptom
briefli
describ
ml
extract
viral
na
put
mlvilo
reaction
incub
hour
superscript
enzym
inactiv
minut
ml
vilo
cdna
reaction
ad
ml
ligat
mix
incub
hour
thirti
microlit
amplif
mix
contain
polymeras
random
primer
ad
amplif
perform
hour
reaction
termin
incub
minut
amplifi
materi
purifi
use
qiaamp
dna
mini
kit
qiagen
use
modifi
protocol
wwwqiagencom
check
puriti
concentr
use
nanodrop
spectrophotomet
thermo
scientif
agaros
gel
electrophoresi
dna
store
immedi
use
microarray
analysi
quantif
viru
virusspecif
realtim
pcr
perform
inhous
assay
bkv
rota
astroviru
ev
rsv
detect
human
gdna
inhous
assay
bactin
use
minut
cycl
second
minut
forward
primer
ctc
ttc
cag
cct
tcc
ttc
ct
revers
primer
agc
act
gtg
ttg
gcg
tac
ag
probe
yakima
yellowtgg
agt
cct
gtg
gca
tcc
acg
abhq
addit
previous
publish
assay
use
jcv
hcv
sapoviru
multihpv
posit
sampl
determin
routin
clarth
microarray
genomica
hpv
pcr
perform
quantit
analysi
bkv
use
inhous
standard
contain
copiesml
confirm
addit
virus
found
microarray
analysi
inhous
realtim
pcr
use
picobirnaviru
rota
c
dengu
subtyp
previous
publish
assay
jcv
gb
viru
type
c
gbvc
human
adenoviru
c
hadvc
thermal
cycl
perform
thermal
cycler
stratagen
appli
biosystem
fold
differ
calcul
dct
obtain
realtim
pcr
result
combin
dilut
factor
sampl
also
made
assumpt
chang
ctvalu
equival
doubl
target
dna
microarray
use
llmda
version
develop
lawrenc
livermor
nation
laboratori
llnl
usa
alreadi
describ
elsewher
briefli
llmda
contain
probe
design
sequenc
viru
bacteria
result
larg
number
probe
cover
genom
microarray
design
detect
discoveri
identifi
known
organ
detect
unsequenc
emerg
organ
strain
subtyp
identif
goal
array
conserv
uniqu
probe
within
famili
oligo
conserv
extent
possibl
within
famili
uniqu
rel
famili
kingdom
priorit
label
microarray
hybrid
perform
nimblegen
systemsiceland
iceland
inhous
ssi
denmark
accord
manufactur
protocol
gene
express
analysi
roch
nimblegen
briefli
mg
heatdenatur
wtaamplifi
sampl
label
use
nick
translat
random
nonam
primer
trilink
biotechnolog
klenow
fragment
exo
neb
hour
label
dna
isopropanol
precipit
pellet
wash
dri
reconstitut
quantit
hybrid
inhous
assay
use
mg
label
dna
wherea
nimblegen
systemsiceland
use
mg
hybrid
perform
nimblegen
hybrid
system
use
nimblegen
hybrid
kit
roch
nimblegen
microarray
scan
use
genepix
scanner
molecular
devic
data
analys
use
maximum
likelihood
method
develop
llnl
extens
describ
elsewher
addit
stringenc
criteria
appli
exclud
bacteri
sequenc
virus
fewer
probe
detect
expect
briefli
probe
classifi
detect
intens
exceed
threshold
equal
th
percentil
intens
neg
control
probe
except
one
sampl
analys
use
th
percentil
target
intern
databas
viral
sequenc
develop
llnl
screen
stringenc
criteria
uncondit
logodd
score
presenc
remain
target
comput
target
logodd
score
less
exclud
greedi
forward
select
algorithm
appli
find
collect
target
like
present
sampl
everi
forward
select
step
condit
logodd
score
comput
remain
target
repres
potenti
contribut
loglikelihood
condit
presenc
previous
select
target
target
largest
condit
logodd
select
ad
collect
result
condit
uncondit
logodd
score
plot
bar
graph
format
condit
logodd
score
show
contribut
target
explain
anoth
like
target
uncondit
score
illustr
similar
target
share
number
probe
multipl
target
may
consist
hybrid
signal
complement
anoth
mode
data
analysi
develop
ssi
data
process
use
nimblescan
softwar
program
nimblegen
roch
mean
intens
probeset
calcul
outlier
intens
within
probeset
filter
signal
standard
deviat
mean
probeset
signal
threshold
defin
th
percentil
random
control
intens
everi
probeset
mean
contain
signal
threshold
consid
posit
signal
microarray
data
submit
gene
express
omnibu
geo
databas
http
ncbinlmnihgovgeo
access
number
microarray
data
use
studi
miam
compliant
remov
contamin
human
gdna
present
clinic
sampl
design
pretreat
protocol
includ
centrifug
filtrat
dnase
treatment
demonstr
filtrat
dnase
rnase
treatment
increas
effici
downstream
amplif
dnase
treatment
viral
na
protect
insid
viral
particl
pretreat
viral
particl
lyse
viral
na
purifi
later
use
genomiphi
amplif
kit
ge
healthcar
purif
addit
carrier
rna
improv
yield
interf
downstream
therefor
left
data
shown
quantit
analysi
viral
dna
human
gdna
pretreat
done
realtim
pcr
figur
tabl
centrifug
filtrat
left
larg
amount
human
gdna
still
present
sampl
ct
dnase
treatment
reduc
signal
ct
figur
dnase
treatment
also
effect
result
decreas
viru
signal
dnase
treatment
tabl
howev
accompani
much
larger
fold
increas
compar
without
dnase
treatment
eg
compar
result
lower
ctvalu
viral
dna
avail
downstream
analysi
tabl
also
seen
rna
viru
hcv
tabl
well
dna
rna
virus
data
shown
investig
extent
remain
human
gdna
would
occur
perform
timecours
experi
amplificationtim
extend
hour
figur
signal
still
accept
background
level
increas
signal
signal
show
increas
signal
conclus
pretreat
remov
signific
amount
human
gdna
allow
good
viru
amplif
establish
amplif
protocol
suitabl
dna
rna
virus
use
describ
method
wta
includ
ligat
step
prior
amplif
step
therebi
gener
larger
templat
wta
perform
hcv
serum
sampl
rna
viru
result
increas
signal
figur
tabl
compar
without
ligat
data
shown
wta
rtreaction
ligat
step
advers
effect
perform
dnaviru
jcv
csf
sampl
figur
tabl
enabl
us
run
viral
dna
rna
amplif
protocol
prior
microarray
hybrid
wta
use
differ
dna
rna
virus
found
differ
type
clinic
sampl
tabl
figur
fold
increas
pcr
signal
compar
wta
rang
highest
fold
increas
detect
circular
virus
jcv
bkv
hpv
tabl
figur
circular
genom
previous
shown
effici
amplifi
polymeras
roll
circl
amplif
rca
lowest
increas
signal
seen
rota
found
faec
tabl
due
larg
quantiti
present
alreadi
amplif
ct
result
ctvalu
tabl
fold
increas
pcr
signal
gdna
bactin
analys
sampl
repres
type
clinic
sampl
show
low
level
bactin
amplif
tabl
wtaamplifi
sampl
purifi
typic
yield
hour
wta
mg
data
shown
show
good
size
distribut
figur
sampl
amplifi
wta
repres
differ
type
clinic
sampl
label
hybrid
llmda
figur
tabl
microarray
data
analys
use
maximum
likelihood
method
develop
llnl
addit
stringenc
appli
clinic
sampl
expect
viru
detect
bkv
jcv
rota
astroviru
sapoviru
dengu
hcv
duplic
ev
rsv
tabl
rsv
sampl
detect
threshold
equal
th
percentil
control
probe
use
detect
sampl
also
use
data
analysi
develop
ssi
rsv
detect
use
detect
threshold
equal
th
percentil
random
control
probe
data
shown
moreov
use
approach
sampl
gener
result
seen
maximum
likelihood
method
data
shown
doubleposit
faec
sampl
contain
astroand
sapoviru
astroviru
detect
microarray
analysi
neg
control
virus
detect
clinic
sampl
repres
type
clinic
sampl
use
studi
skin
lesion
urin
csf
cervic
smear
serum
faec
ta
virus
anellovirida
famili
found
torqu
teno
viru
ttv
torqu
teno
midi
viru
ttmv
ttvlike
mini
viru
tabl
detect
sampl
contain
dna
rna
virus
demonstr
pretreat
amplif
protocol
follow
microarray
analysi
easili
detect
type
one
sampl
addit
virus
detect
sampl
tabl
data
shown
logodd
score
rang
clinic
irrelev
sinc
phage
propionibacterium
phage
phage
lactococcu
phage
enterobacteria
phage
mycobacteriophag
pseudomona
phage
plant
virus
pepino
mosaic
viru
probabl
digest
environment
sourc
data
shown
human
endogen
retroviru
detect
dengu
rsv
sampl
tabl
rest
addit
virus
found
picobirnaviru
hadvc
gbvc
jcv
rota
c
dengu
test
virusspecif
pcr
confirm
tabl
data
shown
cir
dsdna
detect
sampl
present
microarray
use
routin
hpv
diagnosi
genomica
instead
presenc
confirm
use
pcr
rota
faec
sampl
found
posit
picobirnaviru
dsrna
neg
rota
c
dsrna
pcr
sapoviru
faec
sampl
found
posit
hadvc
linear
dsdna
microarray
analysi
confirm
pcr
two
separ
microarray
experi
detect
gbvc
ssrna
hcv
sampl
confirm
gbvcspecif
pcr
bkv
sampl
detect
posit
jcv
microarray
test
neg
pcr
dengu
sampl
found
posit
dengu
microarray
analysi
test
neg
type
use
dengu
subtypespecif
pcr
investig
detect
rang
microarray
clinic
sampl
perform
analysi
urin
sampl
posit
circular
viru
bkv
tabl
figur
sampl
rang
copiesml
bkv
amplifi
polymeras
hour
use
replig
midi
kit
qiagen
also
includ
three
dilut
bkv
urin
sampl
contain
copiesml
respect
sampl
contain
copiesml
bkv
effici
amplifi
yield
copiesml
bkv
tabl
figur
mg
dna
gener
amplif
data
shown
total
input
viral
copi
per
ml
genom
copi
respect
tabl
amplif
sampl
contain
copiesml
result
loss
reproduc
low
yield
tabl
figur
total
input
viral
copi
per
two
sampl
respect
tabl
theoret
amplif
sampl
contain
copiesml
mean
viral
copi
ad
reaction
result
stochast
problem
due
unequ
distribut
highli
dilut
solut
four
amplif
select
microarray
analysi
hybrid
llmda
tabl
figur
analys
use
data
analysi
method
develop
ssi
bkv
urin
sampl
contain
copi
ml
clearli
detect
microarray
analysi
figur
human
genom
sequenc
synovi
sarcoma
x
breakpoint
use
hybrid
control
signal
intens
microarray
crosshybrid
jcv
seen
sampl
bkv
detect
even
neg
jcvspecif
pcr
data
shown
similar
bkv
sampl
present
tabl
conclud
littl
copi
input
copiesml
bkv
genom
abl
gener
enough
materi
clear
detect
microarray
analysi
use
wta
viral
amplif
dna
rna
virus
could
run
protocol
correct
dna
rna
viru
detect
sampl
repres
divers
set
clinic
materi
moreov
correctli
detect
multipl
subtyp
viru
present
sampl
seen
two
clinic
sampl
posit
multipl
hpv
subtyp
respect
crosshybrid
toward
subtyp
furthermor
eva
coxsackieviru
clearli
detect
without
crosshybrid
toward
speci
sever
serotyp
includ
larg
enteroviru
genu
evbcd
rhinoviru
abc
note
subtyp
identif
goal
probe
design
develop
llmda
nevertheless
abil
combin
signal
multipl
probe
analysi
made
possibl
discrimin
differ
subtyp
sever
sampl
analys
one
viru
found
case
includ
dna
rna
virus
taken
togeth
demonstr
potenti
real
life
util
microarray
techniqu
broadspectrum
pathogen
detect
clinic
sampl
sampl
found
virus
previous
test
routin
analysi
cervic
smear
sampl
picobirnaviru
rota
faec
sampl
hadvc
sapoviru
faec
sampl
gbvc
hcv
serum
sampl
two
virus
within
famili
test
gbvc
two
differ
famili
picobirnaviru
hadvc
picobirnaviru
dsrna
viru
picobirnavirida
found
togeth
dsrna
viru
rota
reovirida
hadvc
dsdna
viru
adenovirida
found
togeth
ssrna
viru
sapoviru
calicivirida
fals
detect
viru
sampl
within
famili
previous
test
routin
analysi
jcv
bkv
urin
sampl
rota
c
rota
faec
sampl
dengu
dengu
serum
sampl
could
explain
crossreact
probe
target
one
speci
speci
viral
famili
futur
improv
current
probe
design
address
crossreact
issu
describ
regard
failur
detect
sapoviru
doubleposit
astroviru
sapoviru
faec
sampl
believ
reason
poor
amplif
due
low
viral
copi
number
rather
specif
problem
sinc
sapoviru
detect
sapoviru
faec
sampl
tabl
support
sapovirusspecif
pcr
use
tabl
indic
singleposit
sampl
amplifi
sapoviru
ct
amplif
compar
doubleposit
sampl
ct
therebi
suffici
amount
success
detect
microarray
analysi
microarray
analysi
ttv
relat
virus
detect
sampl
differ
type
clinic
sampl
believ
first
report
regard
preval
ttv
relat
virus
clinic
sampl
denmark
ttv
virus
report
frequent
infect
human
much
certain
popul
direct
evid
link
specif
clinic
diseas
circular
genom
cir
ssdna
effici
amplifi
polymeras
rca
microarray
llmda
could
use
tool
number
way
sinc
enabl
simultan
detect
virus
well
bacteria
could
use
eg
diagnosi
sexual
transmit
diseas
respiratori
ill
combin
viral
bacteri
compon
furthermor
mani
virus
caus
symptom
clinic
similar
make
hard
choos
correct
diagnost
analysi
case
clinic
hypothesi
failur
microarray
could
use
tool
find
etiolog
agent
sampl
presum
neg
sampl
unknown
etiolog
microarray
could
also
play
dual
role
combin
diagnost
research
suitabl
research
tool
find
new
pathogen
could
also
great
valu
epidemiolog
surveil
clinic
unimport
virus
virus
unknown
consequ
carrier
eg
ttv
retrovirus
other
could
found
describ
follow
human
anim
popul
protocol
establish
enabl
us
get
proof
concept
microarray
analysi
use
correctli
identifi
virus
present
divers
set
clinic
sampl
howev
protocol
moment
time
labour
intens
use
figur
microarray
analysi
perform
wtaamplifi
clinic
sampl
result
microarray
data
analysi
wtaamplifi
clinic
sampl
use
maximum
likelihood
method
develop
llnl
addit
stringenc
criteria
appli
lighter
darkercolour
portion
bar
repres
uncondit
condit
logodd
score
respect
condit
logodd
score
show
contribut
target
explain
anoth
like
target
uncondit
score
illustr
similar
target
share
number
probe
routin
set
current
focus
reduc
overal
assay
time
cost
develop
suitabl
protocol
routin
usag
incub
time
throughout
protocol
might
shorten
assay
substitut
combin
make
cheaper
faster
perform
furthermor
microarray
design
chang
multiplex
eg
offer
roch
nimblegen
system
instead
use
increas
number
sampl
run
per
slide
futur
data
analysi
softwar
need
custom
routin
diagnost
analysi
regard
data
handl
easytous
cost
assay
moment
hundr
dollar
per
sampl
establish
refin
techniqu
cost
estim
drop
significantli
probabl
never
level
compar
pcr
howev
benefit
assay
replac
hundr
pcr
reaction
one
reaction
often
hospit
request
one
pcr
assay
per
patient
search
correct
diagnos
furthermor
sinc
microarray
also
contain
probe
bacteria
combin
viral
bacteri
diagnost
anoth
benefit
dna
rna
virus
analys
use
protocol
recent
year
wga
mda
appli
extens
enabl
research
get
enough
materi
littl
singl
cell
downstream
analysi
polymeras
amplifi
access
dna
present
sampl
includ
exogen
dna
contamin
viral
bacteri
diagnost
purpos
presenc
rather
abund
import
main
concern
contamin
human
gdna
compet
pathogen
dna
show
pretreat
reduc
impact
gdna
therebi
allow
greater
amplif
viral
dna
howev
case
enough
due
larg
amount
gdna
present
complet
remov
combin
low
viral
copi
number
might
make
certain
type
clinic
sampl
less
suitabl
effici
amplif
microarray
analysi
current
investig
microarray
analysi
bkv
urin
sampl
indic
littl
genom
copi
circular
dna
genom
could
enough
gener
enough
materi
enabl
success
identif
llmda
high
sensit
might
achiev
type
viral
genom
therefor
investig
furthermor
increas
chanc
produc
enough
materi
low
copi
number
sampl
found
wta
reaction
allow
run
complet
hour
sampl
volum
use
purif
could
also
increas
result
show
protocol
establish
pretreat
amplif
follow
microarray
analysi
use
method
potenti
could
optim
simplifi
current
way
multipl
analys
diagnost
laboratori
support
inform
tabl
repres
exampl
effect
dnasetreat
viru
doc
